Express News | Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
Moomoo 24/7Apr 25 05:29 ET
PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101) IN PARTNERSHIP WITH PNOC SCIENTIFIC CONSORTIUM AND DAY ONE BIOPHARMACEUTICALS
The Pediatric Neuro-Oncology Consortium Foundation (PNOC Foundation), a platinum rated non-profit dedicated to supporting advancements in childhood...
PR NewswireApr 24 15:16 ET
Day One Slips Despite Ojemda Approval as BofA Says Label "not a Home Run"
Seeking AlphaApr 24 15:05 ET
Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
TipRanksApr 24 08:13 ET
Express News | Day One Biopharmaceuticals Inc : Needham Raises Target Price to $33 From $30
Moomoo 24/7Apr 24 07:13 ET
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
TipRanksApr 24 06:21 ET
Day One Biopharm Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Day One Biopharm Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow JonesApr 24 06:19 ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
TipRanksApr 24 05:42 ET
Day One Biopharm Is Maintained at Buy by Needham
Day One Biopharm Is Maintained at Buy by Needham
Dow JonesApr 24 05:38 ET
Express News | Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33
Moomoo 24/7Apr 24 05:28 ET
Day One's OJEMDA (Tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG), the Most Common Form of Childhood Brain Tumor
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
GlobeNewswireApr 23 15:56 ET
Buy Rating on Day One Biopharmaceuticals Amid FDA Approval and Strong Market Prospects
TipRanksApr 23 15:05 ET
Express News | Shares of Day One Biopharmaceuticals Rise About 10% as FDA Grants Accelerated Approval for Brain Tumor Therapy
Moomoo 24/7Apr 23 14:37 ET
Day One Biopharmaceuticals' OJEMDA Receives FDA Approval.
InvestingApr 23 14:20 ET
Day One Wins FDA Nod Brain Cancer Therapy, Ojemda
Seeking AlphaApr 23 13:59 ET
Day One Biopharmaceuticals(DAWN.US) Officer Sells US$160.16K in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Officer Blackman Samuel C. sold 10,000 shares of common stock on Apr 18, 2024 at an average price of $16.0163 for a total value of $160.16K.Source: Announcement W
moomoo NewsApr 22 19:20 ET
Express News | JP Morgan Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $36
Moomoo 24/7Apr 22 10:30 ET
Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market Impact
TipRanksApr 22 05:46 ET
Express News | Day One Biopharmaceuticals Inc : Needham Cuts Target Price to $30 From $31: Needham Cuts Target Price to $30 From $31
Moomoo 24/7Apr 19 05:36 ET
Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)
TipRanksApr 16 09:00 ET
No Data
No Data